ES2124308T3 - Composicion estable de polipeptidos. - Google Patents

Composicion estable de polipeptidos.

Info

Publication number
ES2124308T3
ES2124308T3 ES93910827T ES93910827T ES2124308T3 ES 2124308 T3 ES2124308 T3 ES 2124308T3 ES 93910827 T ES93910827 T ES 93910827T ES 93910827 T ES93910827 T ES 93910827T ES 2124308 T3 ES2124308 T3 ES 2124308T3
Authority
ES
Spain
Prior art keywords
polypeptides
stable composition
polypeptide
stabilized
dissolving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93910827T
Other languages
English (en)
Inventor
Robert L Swift
Mee Charles P Du
Anne E Randolph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Application granted granted Critical
Publication of ES2124308T3 publication Critical patent/ES2124308T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Abstract

UN POLIPEPTIDO (INYECTABLE, BIOLOGICAMENTE ACTIVO) SE ESTABILIZA DISOLVIENDO DICHO POLIPEPTIDO FORMANDO UNA SOLUCION LIQUIDA EN UN NEUTRALIZADOR DE CITRATO DE UN PH DE ENTRE 5.0 Y 5.5.
ES93910827T 1992-04-30 1993-04-27 Composicion estable de polipeptidos. Expired - Lifetime ES2124308T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87662592A 1992-04-30 1992-04-30

Publications (1)

Publication Number Publication Date
ES2124308T3 true ES2124308T3 (es) 1999-02-01

Family

ID=25368192

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93910827T Expired - Lifetime ES2124308T3 (es) 1992-04-30 1993-04-27 Composicion estable de polipeptidos.

Country Status (12)

Country Link
EP (1) EP0639202B1 (es)
JP (1) JP3368282B2 (es)
AT (1) ATE173739T1 (es)
AU (1) AU679913B2 (es)
CA (3) CA2573307C (es)
DE (1) DE69322268T2 (es)
DK (1) DK0639202T3 (es)
ES (1) ES2124308T3 (es)
IL (1) IL105533A (es)
MX (1) MX9302509A (es)
TW (1) TW363973B (es)
WO (1) WO1993022335A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
NZ336793A (en) * 1997-01-20 2000-08-25 Japan Energy Corp Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture
US6740454B1 (en) * 1998-07-27 2004-05-25 Kanebo Limited Organic electrolytic cell with a porous current collector
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8496930B2 (en) * 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
KR20080106636A (ko) * 2007-06-04 2008-12-09 동아제약주식회사 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
KR101784231B1 (ko) 2008-06-20 2017-11-08 노파르티스 아게 응집이 감소된 면역글로불린
DK2884996T3 (da) * 2012-08-17 2020-03-09 Intervet Int Bv Immunogen sammensætning af dræbte leptospira-bakterier

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro

Also Published As

Publication number Publication date
CA2636421C (en) 2010-06-29
DK0639202T3 (da) 1999-08-09
IL105533A0 (en) 1993-08-18
IL105533A (en) 1998-12-06
CA2573307C (en) 2011-01-04
AU4118293A (en) 1993-11-29
CA2133205A1 (en) 1993-11-11
CA2133205C (en) 2007-04-17
DE69322268D1 (de) 1999-01-07
ATE173739T1 (de) 1998-12-15
CA2573307A1 (en) 1993-11-11
WO1993022335A1 (en) 1993-11-11
EP0639202A1 (en) 1995-02-22
DE69322268T2 (de) 1999-08-05
EP0639202B1 (en) 1998-11-25
JPH07509691A (ja) 1995-10-26
AU679913B2 (en) 1997-07-17
MX9302509A (es) 1994-05-31
JP3368282B2 (ja) 2003-01-20
CA2636421A1 (en) 1993-11-11
TW363973B (en) 1999-07-11

Similar Documents

Publication Publication Date Title
ES2124308T3 (es) Composicion estable de polipeptidos.
DE3686654D1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
DE69233188D1 (de) Hormonanaloge mit mehreren ctp-erweiterungen
DE332222T1 (de) Intrascheidenabgabe von aktiven polypeptiden.
DE69810481D1 (de) Stabilisierte antikörperformulierung
BE904831A (fr) Composition d'activateur tissulaire du plasminogene.
ES2113354T3 (es) Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
DE3851455D1 (de) Biologisch wirksame Moleküle.
ATE116333T1 (de) Biologisch aktive moleküle.
DK661888A (da) Biologisk aktive molekyler
ATE48616T1 (de) Analoge von hypokalzemischen polypeptiden, welche den kalziumgehalt des koerpers schonen, deren herstellung, deren verwendung als arznei und diese enthaltende zusammensetzungen.
SE9101586L (sv) Modifierat tioredoxin och dess anvaendning

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639202

Country of ref document: ES